FDA Drastically Reduces Use of This COVID Vaccine Over Blood Clots
The Food and Drug Administration (FDA) announced Thursday it is significantly limiting use of Johnson & Johnson’s COVID-19 vaccine due to a risk of rare but severe blood clots.
The agency announced it is limiting the single-shot vaccine’s authorization to individuals who are either unable to get one of the available mRNA vaccines from Pfizer and Moderna, either due to a lack of access or a medical issue, or to individuals who will not otherwise get vaccinated unless it is by the Johnson & Johnson shot.
The U.S. Food and Drug Administration (FDA) said on Thursday it was limiting the use of Johnson & Johnson's COVID-19 vaccine for adults due to the risk of a rare blood clotting syndrome. https://t.co/SKywihMxsq
— Reuters Health (@Reuters_Health) May 5, 2022
The FDA briefly paused the use of Johnson & Johnson’s shot last year, due to reports that some recipients were developing thrombosis with thrombocytopenia syndrome (TTS). The pause was lifted within weeks, as it was determined only 15 individuals out of eight million vaccine recipients developed the syndrome. (Read more from “FDA Drastically Reduces Use of This COVID Vaccine Over Blood Clots” HERE)
Delete Facebook, Delete Twitter, Follow Restoring Liberty and Joe Miller at gab HERE.
